Mohamed Shalaby

Dr. Mohamed Shalaby


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2020 in JGH Open
Verified
Journal Article
Open access
PDF file
MSMohamed Shalaby
Mohamed Shalaby
TBTarek S El Baradie
Tarek S El Baradie
MSMohamed Salama
Mohamed Salama
HSHebat A M Shaaban
Hebat A M Shaaban
RARasha Mahmoud Allam
Rasha Mahmoud Allam
AAAmr Attia
Amr Attia
Background and Aim: Colorectal cancer (CRC) accounts for over 8% of all deaths each year, with 1.2 million new cases diagnosed annually worldwide. It represents the seventh most common cancer in Egypt. Early detection of peritoneal metastasis is a major challenge in such cases. It helps with the decision of the immediate application of intraperitoneal chemotherapy after resection. Meta‐analysis studies reported contrast evidence for a possible prognostic role of intraperitoneal free cancer cells (IPCCs) in peritoneal recurrence and survival after curative resection. In this work, we aim to evaluate the prevalence and impact of detecting free malignant cells in peritoneal fluid on survival and local recurrence and to estimate the incidence of peritoneal carcinomatosis (PC) during follow up.Methods: Design: This was a prospective cohort study. Settings: From June 2016 to December 2018, samples were collected from 104 patients who underwent abdominal surgery for colorectal cancer in the Egyptian National Cancer Institute. A total of 96 Egyptian CRC patients who underwent curative resection were enrolled. Intraoperative peritoneal lavage was performed to detect IPCC by conventional cytology. Patients with no residual tumor after surgery and no evidence of PC were followed up for a median 14 months. The cumulative 12‐month overall survival rate for patients with IPCC was 100% versus 86% for patients with negative cytology.Results: Our results demonstrated that the prevalence of IPCC in the peritoneal lavage was 11.5%. Peritoneal and local recurrence occurred at a higher rate in patients with cytology positive lavage (9.1% vs 6.3% and 9.1% vs 3.8%, respectively), although this was statistically insignificant. Distant metastasis occurred significantly in patients with positive cytology (45.5% vs 8.9%) with P‐value <0.001.The conventional cytology technique has a high specificity but less sensitivity.Conclusions: The presence of IPCC using conventional cytology was not an independent prognostic factor for the development of PC or survival.

15 December 2025 in Journal of the Egyptian National Cancer Institute
Verified
Journal Article
Open access
PDF file
MSMustafa Selim
Mustafa Selim
HHHanafy Hafez
Hanafy Hafez
AEAbeer Elsayed
Abeer Elsayed
MSMohamed Shalaby
Mohamed Shalaby
AAAbdalwahab R. Abdalwahab
Abdalwahab R. Abdalwahab
MFMohamed Fawzy
Mohamed Fawzy
Background: Intermediate-risk (IR) neuroblastoma represents a biologically and clinically diverse group of tumors. This study evaluates the feasibility of surgical excision and identifies prognostic factors that influence survival in IR-neuroblastoma patients, particularly those with suboptimal responses to induction chemotherapy. Methods: We conducted a retrospective analysis of 50 pediatric patients diagnosed with IR-neuroblastoma at a tertiary cancer center between 2007 and 2016. Treatment responses, surgical outcomes, and survival data were assessed. Prognostic variables were evaluated using univariable and multivariable models. Results: After four cycles of induction chemotherapy, 26% of patients showed an objective response, increasing to 62% by treatment completion. Surgical resection was performed in 70% of patients, with a higher proportion among non-responders. Initial response to induction chemotherapy was a significant independent predictor of surgical feasibility ( p = 0.022) and final disease status ( p = 0.026). Five-year overall survival (OS) was 84%, and event-free survival (EFS) was 72%. Surgical resection significantly improved end-of-treatment disease status in slow-responder patients but did not independently affect OS or EFS. Conclusion: Moderate-intensity chemotherapy with or without surgery provides acceptable survival outcomes in IR-neuroblastoma. An early favorable response to induction therapy may justify avoiding surgery, while surgical resection remains critical for slow-responder patients.

19 December 2024 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MSMohamed Shalaby
Mohamed Shalaby
RARasha M. Allam
Rasha M. Allam
MEMohamed A. Elkordy
Mohamed A. Elkordy
MTMohammad Taher
Mohammad Taher

1 May 2022 in The Egyptian Journal of Fertility and Sterility
Verified
Journal Article
Open access
PDF file
MSMohamed Shalaby
Mohamed Shalaby